Press releases

29 March, 2019

Regulatory

Amended number of shares and votes in NeuroVive Pharmaceutical AB (publ)

Lund, Sweden, 29 March 2019 - NeuroVive Pharmaceutical AB(Nasdaq Stockholm: NVP, OTCQX: NEVPF), today announced an increase of the number of shares and votes in NeuroVive of 22,594,467 as a result of ...

25 March, 2019

Regulatory

NeuroVive Pharmaceutical AB publishes 2018 Annual report

Lund, Sweden, 25 March 2019, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the English version of the Annual report for 2018 is now available on the company’s ...

25 March, 2019

Regulatory

Notice of Annual General Meeting of Shareholders in NeuroVive Pharmaceutical AB (publ)

The Board of Directors of NeuroVive Pharmaceutical AB (publ) has issued a notice to the Annual General Meeting, which is to take place on Thursday, April 25, 2019, at 4 pm at Medicon Village, Scheelev ...

19 March, 2019

Regulatory

NeuroVive enrolls first subject in its KL1333 phase Ia/b clinical study

Lund, Sweden, 19 March 2019, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the first healthy volunteer in the company’s KL1333 phase Ia/b study has been screen ...

7 March, 2019

Regulatory

NeuroVive receives SEK 28.2 Million in a directed new share issue

Lund, Sweden, 7 March 2019, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the company has successfully conducted a directed new issue of shares, which has rais ...

28 February, 2019

Regulatory

Amended number of shares and votes in NeuroVive Pharmaceutical AB (publ)

Lund, Sweden, 28 February 2019 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), today announced an increase of the number of shares and votes in NeuroVive of 71,661,048 as a result ...

28 February, 2019

Regulatory

NeuroVive Pharmaceutical AB Year End Report January – December 2018

Positioned for clinical progress

21 February, 2019

NeuroVive enters commercial partnership with Oroboros Instruments on mitochondrial medicine research compounds

Lund, Sweden, 21 February 2019 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the company has entered into an exclusive agreement to license and supply two of ...

11 February, 2019

Regulatory

NeuroVive is supplied with approximately MSEK 99.0 in share issue proceeds

Lund, February 11, 2019 - NeuroVive Pharmaceutical AB (publ) ("NeuroVive" or the "Company") (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced the outcome of the preferential rights issue of shares ...

25 January, 2019

Regulatory

NeuroVive’s Board Members, Senior Executives and employees have subscribed to shares in the ongoing rights issue

In the current rights issue in NeuroVive, the Board, Senior Executives and employees have undertaken to subscribe for at least 1,778,995 shares equivalent to MSEK 2.4 which exceeds current holdings.

22 January, 201919 February, 2024

Regulatory

NeuroVive publishes prospectus in connection with preferential rights issue

Lund, Sweden, 22 January 2019 – NeuroVive Pharmaceutical AB (publ) (Nasdaq Stockholm: NVP, OTCQX: NEVPF) announced today that the prospectus in connection with NeuroVive Pharmaceutical AB’s (publ) (“N ...

18 January, 2019

NeuroVive – company presentations January 2019

Lund, Sweden, 18 January 2019 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX:NEVPF) informs on its scheduled company presentation for January 2019.